Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells

Journal of Immunology

Volumn 165, Issue 4, 2000, Pages 1854-1862

  Mueller, C M ^a   Scott, D W ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISINDOLYLMALEIMIDE; CASPASE 8; CYCLOHEXIMIDE; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

EID: 0034662857     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.4.1854     Document Type: Article

References (63)

1. Apoptosis and the maintenance of homoestasis in the immune system
2. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens
3. Fas and Fas ligand: Lpr and gld mutations
4. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
5. + T cells
6. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions
7. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis
8. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
9. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
10. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
11. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease
12. B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1β-converting enzyme protease and regulating Bcl-2/Bcl-x expression
13. + normal B cells
14. Differential susceptibility to tolerance induction in vitro of splenic B cells from several transgenic mouse lines: Role of B1 cells
15. Lymphoma models for B-cell activation and tolerance. IV. Growth inhibition by anti-Ig of CH31 and CH33 B lymphoma cells
16. Immunoglobulins D and M mediate signals that are qualitatively different in B cells with an immature phenotype
17. Lymphoma models for B cell activation and tolerance. I. Conditions for the anti-μ-dependent stimulation of growth in NBL, a nude B-cell lymphoma
18. Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-μ of WEHI-231 and the selection properties of resistant mutants
19. Functional subsets of murine and human B lymphocyte cell lines
20. The target cell nucleus is not required for cell-mediated granzyme- or Fas-based cytotoxicity
21. The c-myc oncogene driven by the immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
22. Establishment and characterization of BALB/c lymphoma lines with B cell properties
23. Clonal outgrowths of T and B cells in SCID mice reconstituted with cells from mice with MAIDS
24. Cell death attenuation by 'Usurpin,' a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD95 (Fas, APO-1) receptor complex
25. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: Involvement of NF-κB activation in drug resistance
26. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells
27. Regulation of bcl-x(L) expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM cross-linking and IL-4
28. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor
29. Fas ligation induces apoptosis of CD40-activated human B lymphocytes
30. Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells
31. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
32. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
33. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-in-dependent multiple myeloma cell lines
34. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ
35. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
36. Mutations in the Fas antigen in patients with multiple myeloma
37. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells
38. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
39. Down-regulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells
40. IL-4 induces Fas resistance in B cells
41. Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded
42. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells
43. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases
44. Regulation of germinal center B cell differentiation: Role of human APO-1/Fas (CD95) molecule
45. The Bcl-2 protein family: Arbiters of cell survival
46. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism
47. Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB
48. Analysis of the role of protein kinase C-α, -ε, and -ζ in T cell activation
49. Protein kinase Cμ down-regulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-κB-dependent protective genes
50. An essential role for NF-κB in preventing TNF-α-induced cell death
51. Suppression of TNF-α-induced apoptosis by NF-κB
52. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas
53. Role of reactive oxygen intermediates in activation-induced CD95 (APO/Fas) ligand expression
54. Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T cell lymphoma Hut-78 cells: Autocrine role of tumor necrosis factor and reactive oxygen intermediates
55. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
56. Human lung carcinomas express Fas ligand
57. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
58. Constitutive expression of Fas ligand in large granular lymphocyte leukemia
59. Fas ligand in human serum
60. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand
61. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
62. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
63. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis